The Role of Chemotherapy in Anaplastic Astrocytoma Patients by Kim, Sung Kwon et al.
199
to evaluate the role of chemotherapy for survival outcome. 
MATERIALS AND METHODS
A total of 86 newly diagnosed AA patients between 1990 and 
2004, were included in this single-center retrospective study. All 
patients were histologically proved to be AA according to the 
WHO 2007 classification after surgical resection in 47 and ste-
reotactic biopsy in 399). The median age was 40.9 years (range, 
18-70 years), 39 patients were male and 47 patients were fe-
male. Preoperative brain magnetic resonance images revealed 
that 47 patients had enhancing lesion while 39 patients had no 
focal lesion of enhancement. Performance status after surgery 
expressed by Karnofsky performance score (KPS) of a whole 
group was good enough to be same of more than 70 in 82 pa-
tients (95.4%).
Three different treatment protocols were applied to patients 
with AA enrolled in this study. Among them, 31 patients (36.0%) 
INTRODUCTION
The survival of patients with malignant glioma remains poor, 
with a median survival of 2 to 3 years for patients with anaplas-
tic astrocytoma (AA) albeit the advancement of treatments in-
cluding surgical resection, radiation therapy, and chemothera-
py3). Also, the standard treatment for AA has been stagnant for 
decades with surgery followed by radiotherapy only1,14). The 
role of chemotherapy for AA is not fully established although 
the possibilities of benefit for prolonging of survival had been 
proposed2,13-15). Establishment of standard management proto-
cols for AA is even more difficult due to its low incidence which 
is the major obstacle in designing the large-scale randomized 
prospective study. Many previous studies for the management 
of malignant glioma pooled both grades III or IV astrocytic tu-
mors, and need for separate study for AA was advocated after 
sub-analysis of the study population6,8,10). In this study, we ana-
lyzed a relatively large series of 86 newly diagnosed AA patients 
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42 and 9 patients underwent only biopsy. The median age for 
ACNU-CDDP group was 40.5. Among them, 15 patients un-
derwent biopsy. In three groups, the most of patients had above 
70 KPS score. Table 1 summarizes the baseline characteristics of 
each group and shows that they are well-balanced. 
Salvage treatments were performed to each groups during 
clinical observation period. Various protocols of salvage che-
motherapy including PCV, ACNU-CDDP, amd temozolomide 
(TMZ) were tried. The chemotherapy was chosen according to 
the physicians’ decision and clinical patients’ status. Toxic ef-
fects were graded in accordance with the NCI CTCAE, version 
3.0. Statistical analysis included ANOVA and chi-square test for 
parametric comparisons. All statistical significance was accept-
ed at probability values of less than 0.05. The Kaplan-Meyer 
method was used to estimate the overall survival distributions. 
The log-rank test was used to test the differences in the overall 
survival distributions with respect to the treatment groups. A 
Cox proportional hazards model was used to adjust for covari-
ates. These analyses were performed using SPSS® version 12.0.
RESULTS
The median overall survival of the entire population was 29.0 
months [95% confidence interval (CI)=19.97-38.03]. The medi-
an survival was 14.0 months (95% CI=7.8-20.2) in RT group, 
30.0 months (95% CI=21.4-38.6) in ACNU-CDDP group and 
72.0 months (95% CI=52.0-91.9) in PCV group, respectively. 
There were significant differences in estimated survival among 
treatment groups (Fig. 1). PCV group was superior to both RT 
group (p=0.002) and ACNU-CDDP group (p=0.045) in surviv-
al gain. ACNU-CDDP group showed significant survival pro-
longation compared with RT group (p=0.039). If the extent of 
resection was considered for survival analysis significant differ-
ences in estimated survival among treatment groups were ob-
served in both biopsy only population and in resection popula-
tion. In biopsy only population, the median survival was 9.0 
months (95% CI=2.7-15.3) in RT group, 28.0 months (95% 
CI=21.7-34.3) in ACNU-CDDP group and 47.0 months (95% 
CI=35.3-58.7) in PCV group, and their differences were signifi-
cant (p=0.027 between PCV group and RT group and p=0.035 
between ACNU-CDDP group and RT group) except for be-
tween PCV group and ACNU-CDDP group (p=0.2200). On the 
other hand, in resection population, the median survival was 
23.0 months (95% CI=21.1-24.9) in RT group, 38.0 months (95% 
CI=25.4-50.6) in ACNU-CDDP group and 90.0 months (95% 
CI=47.1-132.8) in PCV group and significant difference in esti-
mated survival among treatment groups was observed in only 
between PCV group and RT group (p=0.033). There was no 
significant differences in survival between PCV group and AC-
NU-CDDP group (p=0.192) and between ACNU-CDDP group 
and RT group (p=0.279) in resection population. Overall, add-on 
chemotherapy to radiotherapy was beneficial in survival gain 
compared with radiotherapy alone. Also, adjuvant PCV chemo-
were treated with radiotherapy only (RT Group). The complete 
scheduled radiation dose of 61.2 Gy was delivered and no other 
treatment was added to this group. Another group of 30 pa-
tients (34.9%) were treated with nimustine-cisplatin chemo-
therapy before RT (ACNU-CDDP group). This treatment was 
scheduled to receive 2 cycles of ACNU-CDDP neoadjuvant che-
motherapy, followed by conventional radiotherapy. The neoad-
juvant chemotherapy with ACNU (40 mg/m2/day) and CDDP 
(40 mg/m2/day) was administered by continuous infusion for 
72 h and was repeated after 6 weeks. Among 30 patients, 20 pa-
tients completed 2 cycles of ACNU-CDDP while 10 patients re-
ceived only 1 cycle and proceeded to radiotherapy because of 
toxicity. The other 25 patients (29.1%) were treated with PCV 
(procarbazine, lomustine and vincristine) chemotherapy after 
radiotherapy (PCV group). PCV chemotherapy started within 
4 weeks after the end of radiotherapy. Each cycle consisted of 
lomustine 110 mg/m2 orally on day 1, procarbazine 60 mg/m2 
orally on days 8 to 21, and vincristine 1.4 mg/m2 intravenously 
on days 8 and 29. Cycles were to be repeated every 6 weeks. Due 
to the intolerance, only 5 patients completed all 12 cycles while 8 
patients received 6 to 11 cycles and 12 patients were treated with 
less than 6 cycles of PCV. In the RT group, their median age was 
42 and 16 patients (52%) underwent resection of the mass in-
cluding gross total removal, near total removal, subtotal remov-
al, and partial removal. The other 15 patients underwent biopsy 
only to confirm pathologically. Median age of PCV group was 
Fig. 1. Kaplan-Meier estimates of overall survival according to treatment 
group. Significant differences in estimated survival among treatment 
groups were observed (p=0.002 between PCV group and RT group; 
p=0.045 between PCV group and ACNU-CDDP group; p=0.039 between 
ACNU-CDDP group and RT group). PCV : procarbazine, lomustine and 
vincristine, ACNU-CDDP : nimustine-cisplatin, RT : radiotherapy.
0.0
0.2
0.4
0.6
0.8
1.0
C
u
m
u
l
a
t
i
v
e
 
s
u
r
v
i
v
a
l
 
(
%
)
0 24 48 72 96 120 144 168 192
25
30
31
20
20
10
16
10
  7
11
  3
  2
8
3
2
3
2
3
2
3
2
Months
No. at risk :
PCV
ACNU-CDDP
RT
PCV group
RT group
ACNU-CDDP group201
Chemotherapy in AA | SK Kim, et al.
astrocytic tumors and analyzed the efficacy of treatment proto-
col for whole study population as a same group. However, there 
was need for separate study for AA was advocated after sub-
analysis of the study population6,8). For example, European study 
testing adjuvant chemotherapy combining dibromodulcitol   
and carmustine given postoperatively to patients with newly di-
agnosed supratentorial malignant gliomas resulted in longer 
survival (8.1 months vs. 6.7 months) only in experimental arm 
of subgroup of 29% of non-glioblastoma patients6). In the pres-
ent study, we confined the study population to newly diagnosed 
AA patients and confirmed the beneficial role of add-on chemo-
therapy over radiotherapy alone. Moreover, adjuvant chemo-
therapy with PCV after radiotherapy was proven to be advanta-
geous compared with neo-adjuvant chemotherapy with 
ACNU-CDDP in terms of survival outcome and toxicity rate. 
The limitation of this study, however, should be taken into ac-
count as the retrospective data analysis could not avoid the se-
lection bias at the stage of management decision. The treatment 
therapy was more effective than neo-ad-
juvant ACNU-CDDP chemotherapy. In 
the multivariate analysis, the benefit of 
chemotherapy was confirmed once 
again along with good performance sta-
tus (KPS ≥90) and extent of surgical re-
section (Table 2).
Toxicity associated with treatment was 
also analyzed (Table 3). In the PCV 
group, grade 3 or 4 toxicities were found 
in 5 patients (20%). Among them, 4 pa-
tients (16.0%) showed hematological 
toxicities and one patient (4.0%) showed 
non-hematological toxicity. In the AC-
NU-CDDP group, 12 patients (40%) ex-
perienced grade 3 or 4 toxicities which 
consist of 8 patients (26.7%) for hemato-
logical and 4 patients (13.3%) for non-
hematological toxicities. There was a relatively lower rate of seri-
ous toxicities in RT group that only 3 patients (9.6%) experienced 
grade 3 or 4 toxicities.
DISCUSSION
The focal radiotherapy with a total dose of 60 Gy in 30 daily 
fractions has been the standard treatment for AA on the basis 
of level 1 evidence1). However, the benefit of chemotherapy in 
the treatment of AA remains controversial for many decades. 
Most prospective randomized trials on using chemotherapy for 
malignant gliomas failed to prove their efficacy10,12). Among the 
diverse efforts conducted using chemotherapy for malignant 
gliomas, carmustine and procarbazine showed modest benefit 
for survival outcome5,14). On the other hand, there also have been 
the concerns about considerable toxicities in applying chemo-
therapy to malignant glioma patients4,7). The problem of majori-
ty of previous studies is that they pooled both grades III or IV 
Table 1. Comparison of baseline characteristics among treatment groups
RT group ACNU-CDDP group PCV group p-value
No. of patients 31 (36%)    30 (34.9%)    25 (29.1%)
Enrollment period 1990-2003 1999-2004 1993-1999
Median age 42 40.5 37 0.553
Surgery
    Biopsy 15 (48%) 15 (50%)   9 (36%) 0.560
    Resection 16 (52%) 15 (50%) 16 (64%)
KPS
    100-90    14 (45.1%)    17 (56.7%) 17 (68%) 0.409
    80-70    15 (48.4%)    11 (36.7%)   8 (32%)
    <70    2 (6.5%)    2 (6.6%) 0
Salvage treatment PCV (n=1) 
ACNU-CDDP (n=1)
TMZ (n=4)
PCV (n=2)
PCV & TMZ (n=5)
TMZ (n=3) 
ACNU-CDDP (n=4)
KPS : Karnofsky performance score, PCV : procarbazine, lomustine and vincristine, ACNU-CDDP : nimustine-cisplatin, TMZ : temozolomide, RT : radiotherapy
Table 2. Multivariate Cox proportional-hazards results for the prognostic value of variables related 
to the survival (n=86)
Variable Hazard ratio p-value 95% CI
KPS ≥90 (vs. <90) 0.343 0.000 0.202-0.582
Resection (vs. Biopsy) 0.476 0.005 0.284-0.799
ACNU/CDDP-RT (vs. RT) 0.434 0.007 0.237-0.795
RT-PCV (vs. RT) 0.311 0.000 0.162-0.598
KPS : Karnofsky performance score, PCV : procarbazine, lomustine and vincristine, ACNU-CDDP : nimustine-
cisplatin, RT : radiotherapy, CI : confidence interval
Table 3. Treatment-related toxicities of NCI CTCAE grade
Treatment group
Grade 1 or 2 Grade 3 or 4
Hematologic Non-
hematologic Hematologic Non-
hematologic
PCV (n=25)   4 (16.0%) 18 (72.0%)   4 (16.0%) 1 (4.0%)
ACNU-CDDP (n=30) 10 (33.3%) 16 (53.3%)   8 (26.7%)   4 (13.3%)
RT (n=31) 0 14 (45.2%) 1 (3.2%) 2 (6.4%)
PCV : procarbazine, lomustine and vincristine, ACNU-CDDP : nimustine-cisplatin, RT : radiotherapy202
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protocol between radiotherapy only and add-on chemotherapy 
to radiotherapy was rather randomly chosen according to the 
physicians’ decision throughout the study period. However, che-
motherapy regimen was changed according to the times that 
PCV group was enrolled in 1990s (from 1993 to 1999) and AC-
NU-CDDP group was enrolled in mostly early 2000s (from 
1999 to 2004) (Table 1). The other shortcoming of the present 
study is that there is no consideration of detailed molecular 
markers such as 1p and 19q chromosomal deletion status, O6-
methylguanine methyl transferase promoter methylation status 
or isocitrate dehydrogenase mutation status due to the unavail-
ability of the tumor tissue.
Comparison of efficacy between PCV and nitrosourea also 
showed controversial results in previous studies. Analysis of Ra-
diation Therapy Oncology Group (RTOG) database for newly 
diagnosed AA revealed no difference in survival after radio-
therapy between adjuvant PCV group and adjuvant carmustine 
group11). This trial has been criticized for allowing different ra-
diotherapy schedules and for giving a modified PCV regimen12). 
On the other hand, re-analysis of the Northern California On-
cology Group protocol 6G61 study confirmed superior survival 
outcome of adjuvant PCV group (157.1 weeks) to that of adju-
vant BCNU group (82.1 weeks) after radiotherapy only in AA 
patients8).
Although PCV chemotherapy has more tolerable toxicity pro-
files over ACNU-CDDP chemotherapy as shown in the present 
study, relatively high rate of significant toxicity in both regimens 
makes oncologist to hesitate over immediate application. If 
more tolerable chemotherapy regimen with comparable effica-
cy is proved to be recommendable in on-going trials such as 
TMZ in RTOG 9318 protocol or international CATNON trial, 
new era for standard therapy for AA including chemotherapy 
will come. Until then, adjuvant PCV after radiotherapy in select-
ed AA patients with good performance is expected to give fa-
vorable survival outcome. 
CONCLUSION
An application of chemotherapy before or after radiotherapy 
is beneficial compared with radiotherapy alone in prolonging 
the survival of patients with AA. Adjuvant PCV chemotherapy 
after radiotherapy is recommendable due to its superior surviv-
al outcome and better toxicity profile over neo-adjuvant AC-
NU-CDDP chemotherapy.
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